Abstracts by keywords: Inflammatory Bowel Disease
The body's native and adaptive immune system plays an important role in a variety of diseases such as psoriasis (PSO) [1], inflammatory bowel disease (CD/CU) [2] and rheumatoid arthritis (RA) [3]. These autoimmune diseases result from disruption of pro-inflammatory and anti-inflammatory responses, leading to an immune-mediated attack on the host tissue [4]. Recent decades have seen an increase in the incidence and prevalence of autoimmune diseases, highlighting the importance of appropriate treatment of these diseases [5]. Biologic drugs are treatments aimed at altering the course of autoimmune diseases and represent an important alternative to conventional treatments [6]. The main targets of biological drugs are cytokines (e.g. tumor necrosis factor-α [TNF-α], interleukin-1 [IL-1] or -6 [IL-6]), B cells and costimulation molecules (e.g. T- Cell surface protein CD28 or cytotoxic T lymphocyte-associated antigen-4 [CTLA-4]) [7]. Biological medicines have several advantages such as: B. an established long-term effect, a high selectivity for target molecules, positive cardiovascular effects, their suitability for patients with impaired kidney or liver function and maximum adherence to intake [8].